Inhibitors | Comment | Organism | Structure |
---|---|---|---|
methyl-5-(N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) phenyl)morpholine-4-carboxamido)pentanoate | i.e. CBM-301106, specific inhibitor of the enzyme | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
cardiomyocyte | neonatal | Mus musculus | - |
heart | - |
Mus musculus | - |
macrophage | peritoneal | Mus musculus | - |
Synonyms | Comment | Organism |
---|---|---|
MCD | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
malfunction | pharmacological inhibition of malonyl-CoA decarboxylase reduces the inflammatory response associated with insulin resistance. Additionally, inhibition of MCD strongly diminishes lipopolysaccharide-induced activation of palmitate oxidation and prevents lipopolysaccharide-induced collapse of total cellular antioxidant capacity and prevents increases in the level of ceramide in cardiomyocytes and macrophages while also ameliorating LPS-initiated decreases in PPAR binding. Genetic inactivation of malonyl-CoA decarboxylase protects mice against high-fat diet-induced insulin resistance | Mus musculus |
physiological function | malonyl-CoA decarboxylase regulates fatty acid oxidation | Mus musculus |